This official website is maintained by the Administrator retained and supervised by Co-Lead Counsel for the End-Payor Plaintiff Classes in the case entitled
In re Opana ER Antitrust Litigation, Case No. 1:14-cv-10150 (N.D. Ill.)



Your rights may be affected by a proposed partial settlement in a class action lawsuit regarding the prices paid for brand and generic Opana ER by consumers and third-party payors filed against Defendant Impax Laboratories, Inc. (“Impax”). The case name is In re Opana ER Antitrust Litigation, MDL No. 2580, Lead Case No. 14-cv-10150 (N.D. Ill.) (the “Lawsuit”). The Lawsuit, which is pending in the Northern District of Illinois, alleges that Impax, together with Endo Health Solutions Inc., Endo Pharmaceuticals Inc., and Penwest Pharmaceuticals Co. (collectively, “Endo”) violated certain state antitrust, consumer protection, and unjust enrichment laws by entering into a “pay for delay” or “reverse payment” agreement, delaying the launch of Impax’s generic version of Opana ER until January 2013. As a result, the Lawsuit alleges that the End-Payor Classes paid or reimbursed for brand and generic Opana ER at prices that were higher than they would have otherwise been. Impax denies any wrongdoing. After Plaintiffs settled with Impax, a federal jury determined that as to Endo, Plaintiffs did not meet their burden in showing that Endo violated federal or state laws arising from Plaintiffs’ allegations.

The Court has preliminarily approved the proposed settlement between the End-Payor Classes and Impax (the “Settlement”). The proposed Impax Settlement will provide for the payment of $15 million (the “Settlement Fund”) to resolve the End-Payor Classes’ claims against Impax. The full text of the proposed Settlement Agreement is available on the Court Documents page.

YOUR LEGAL RIGHTS AND OPTIONS
DO NOTHING If you are a member of a Class, by doing nothing you will remain in that Class but will not be entitled to share in any distribution from the Settlement Fund. You will be bound by any decision of the Court in this Lawsuit, including rulings on the Impax Settlement. See Question 11 of the Notice .
SUBMIT A CLAIM FORM If you did not exclude yourself from one or more of the classes prior to the December 6, 2021, deadline and believe you are a Class Member, you will need to complete and return a Claim Form to obtain a share of the Settlement Fund. The Claim Form, and information on how to submit it, are available on the Claim Forms page of the website. Claim Forms must be postmarked (if mailed) or received (if submitted online) on or before January 5, 2023. See Question 7 of the Notice .
OBJECT TO THE SETTLEMENT OR SPEAK AT THE FAIRNESS HEARING If you object to all or any part of the Settlement or desire to speak in person at the Fairness Hearing, you must file a written letter of objection and/or a notice of intention to speak, including a summary statement, with the Court, Co-Lead Counsel, and Counsel for Impax by November 7, 2022. See Question 10 of the Notice .
GET MORE INFORMATION If you would like more information about the Lawsuit, you can review the Notice and send questions to the Claims and Notice Administrator and/or Co-Lead Counsel. See Questions 12 and 18 of the Notice.

DO NOT CONTACT THE COURT OR THE DEFENDANTS IF YOU HAVE QUESTIONS REGARDING THIS NOTICE.





This official website is maintained by the Administrator retained and supervised by Co-Lead Counsel for the End-Payor Plaintiff Classes in the case entitled
In re Opana ER Antitrust Litigation, Case No. 1:14-cv-10150 (N.D. Ill.)


Your rights may be affected by a proposed partial settlement in a class action lawsuit regarding the prices paid for brand and generic Opana ER by consumers and third-party payors filed against Defendant Impax Laboratories, Inc. (“Impax”). The case name is In re Opana ER Antitrust Litigation, MDL No. 2580, Lead Case No. 14-cv-10150 (N.D. Ill.) (the “Lawsuit”). The Lawsuit, which is pending in the Northern District of Illinois, alleges that Impax, together with Endo Health Solutions Inc., Endo Pharmaceuticals Inc., and Penwest Pharmaceuticals Co. (collectively, “Endo”) violated certain state antitrust, consumer protection, and unjust enrichment laws by entering into a “pay for delay” or “reverse payment” agreement, delaying the launch of Impax’s generic version of Opana ER until January 2013. As a result, the Lawsuit alleges that the End-Payor Classes paid or reimbursed for brand and generic Opana ER at prices that were higher than they would have otherwise been. Impax denies any wrongdoing. After Plaintiffs settled with Impax, a federal jury determined that as to Endo, Plaintiffs did not meet their burden in showing that Endo violated federal or state laws arising from Plaintiffs’ allegations.

The Court has preliminarily approved the proposed settlement between the End-Payor Classes and Impax (the “Settlement”). The proposed Impax Settlement will provide for the payment of $15 million (the “Settlement Fund”) to resolve the End-Payor Classes’ claims against Impax. The full text of the proposed Settlement Agreement is available on the Court Documents page.


YOUR LEGAL RIGHTS AND OPTIONS

DO NOTHING
If you are a member of a Class, by doing nothing you will remain in that Class but will not be entitled to share in any distribution from the Settlement Fund. You will be bound by any decision of the Court in this Lawsuit, including rulings on the Impax Settlement. See Question 11 of the Notice .

SUBMIT A CLAIM FORM
If you did not exclude yourself from one or more of the classes prior to the December 6, 2021, deadline and believe you are a Class Member, you will need to complete and return a Claim Form to obtain a share of the Settlement Fund. The Claim Form, and information on how to submit it, are available on the Claim Forms page of the website. Claim Forms must be postmarked (if mailed) or received (if submitted online) on or before January 5, 2023. See Question 7 of the Notice .

OBJECT TO THE SETTLEMENT OR SPEAK AT THE FAIRNESS HEARING
If you object to all or any part of the Settlement or desire to speak in person at the Fairness Hearing, you must file a written letter of objection and/or a notice of intention to speak, including a summary statement, with the Court, Co-Lead Counsel, and Counsel for Impax by November 7, 2022. See Question 10 of the Notice .

GET MORE INFORMATION
If you would like more information about the Lawsuit, you can review the Notice and send questions to the Claims and Notice Administrator and/or Co-Lead Counsel. See Questions 12 and 18 of the Notice.

DO NOT CONTACT THE COURT OR THE DEFENDANTS IF YOU HAVE QUESTIONS REGARDING THIS NOTICE.